Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

AZ and Daiichi Sankyo already claimed FDA approval for the HER2-low indication in the US last summer, adding to Enhertu's lengthening list of indications, which also includes second- and third ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

DEVASTATED Nadia Sawalha fought back tears in an emotional video as she shared some heartbreaking news. Loose Women star Nadia, 60, struggled to contain her emotions while revealing her best ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

Enhertu stands out as a targeted therapy that combines chemotherapy with HER2-focused treatment, delivering improved outcomes for patients with advanced or metastatic HER2-positive breast cancer.

DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...